Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma

Jung Guk Kim

doi:10.3803/EnM.2014.29.3.211

Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma

Jung Guk Kim

Department of Medicine

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-γ, may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies. Vascular endothelial growth factor (VEGF)- and RET-directed therapies such as sorafenib, motesanib, and sunitinib have been shown to be the most effective at inducing clinical responses and stabilizing the disease process. Further clinical trials of these therapeutic agents may soon change the management of thyroid cancer.

Original language	English
Pages (from-to)	211-216
Number of pages	6
Journal	Endocrinology and Metabolism
Volume	29
Issue number	3
DOIs	https://doi.org/10.3803/EnM.2014.29.3.211
State	Published - 2014

Keywords

Targeted therapies
Thyroid neoplasms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3803/EnM.2014.29.3.211

Cite this

@article{416fb70c6b2d4f30a2ce530d89a12626,

title = "Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma",

abstract = "Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-γ, may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies. Vascular endothelial growth factor (VEGF)- and RET-directed therapies such as sorafenib, motesanib, and sunitinib have been shown to be the most effective at inducing clinical responses and stabilizing the disease process. Further clinical trials of these therapeutic agents may soon change the management of thyroid cancer.",

keywords = "Targeted therapies, Thyroid neoplasms",

author = "Kim, {Jung Guk}",

note = "Publisher Copyright: {\textcopyright} 2014 Korean Endocrine Society.",

year = "2014",

doi = "10.3803/EnM.2014.29.3.211",

language = "English",

volume = "29",

pages = "211--216",

journal = "Endocrinology and Metabolism",

issn = "2093-596X",

publisher = "Korean Endocrine Society",

number = "3",

}

TY - JOUR

T1 - Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma

AU - Kim, Jung Guk

PY - 2014

Y1 - 2014

N2 - Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-γ, may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies. Vascular endothelial growth factor (VEGF)- and RET-directed therapies such as sorafenib, motesanib, and sunitinib have been shown to be the most effective at inducing clinical responses and stabilizing the disease process. Further clinical trials of these therapeutic agents may soon change the management of thyroid cancer.

AB - Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-γ, may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies. Vascular endothelial growth factor (VEGF)- and RET-directed therapies such as sorafenib, motesanib, and sunitinib have been shown to be the most effective at inducing clinical responses and stabilizing the disease process. Further clinical trials of these therapeutic agents may soon change the management of thyroid cancer.

KW - Targeted therapies

KW - Thyroid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84947797749&partnerID=8YFLogxK

U2 - 10.3803/EnM.2014.29.3.211

DO - 10.3803/EnM.2014.29.3.211

M3 - Review article

AN - SCOPUS:84947797749

SN - 2093-596X

VL - 29

SP - 211

EP - 216

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

IS - 3

ER -

Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this